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Abstract (250 words) 
Background 
Endogenous hormones are associated with breast cancer risk, but little is known about their role on 
breast-tissue composition, a strong risk predictor. This study aims to investigate the relationship 
between  growth and sex hormone levels and breast-tissue composition in young nulliparous women. 
Methods 
A cross-sectional study of 415 young (aged ~21.5 years) nulliparous women from an English pre-birth 
cohort underwent a magnetic resonance imaging examination of their breasts to estimate percent-
water (a proxy for mammographic percent-density) and provided a blood sample  to measure plasma 
levels of growth factors (insulin-like growth-factor-I, insulin-like growth-factor-II, insulin-growth-factor-
binding-protein-3, growth-hormone) and, if not on hormonal contraception (n=117) sex-hormones 
(dehydroepiandrosterone, androstenedione, testosterone, estrone, estadiol, sex-hormone-binding-
globulin, prolactin). Testosterone (n=330) and sex-hormone-binding-globulin (n=318) were also 
measured at age 15.5 years. Regression models were used to estimate the relative difference (RD) in 
percent-water associated with one standard deviation increment in hormone levels. 
Results 
Estradiol at age 21.5 and sex-hormone-binding-globulin at ages 21.5 were positively associated with 
body mass index (BMI)-adjusted percent-water (RD (95% CI): 3% (0%, 7%) and 3% (1%, 5%), 
respectively). There was a positive non-linear association between androstenedione at age 21.5 and 
percent-water. Insulin-like-growth-factor-I and growth-hormone at age 21.5 were also positively 
associated with BMI-adjusted percent-water (RD (95% CI): 2% (0%, 4%) and 4% (1%, 7%), 
respectively).  
Conclusion 
The findings suggest that endogenous hormones affect breast-tissue composition in young 
nulliparous women. 
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Impact 
The well-established associations of childhood growth and development with breast cancer risk may 
be partly mediated by the role of endogenous hormones on breast-tissue composition.  
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Introduction 
The risk of developing breast cancer has been associated with several hormone-related exposures. 
Early age of menarche, late age of menopause and use of hormonal contraceptives and menopausal 
hormone therapy (HT), factors that act as proxy measures for an increased lifetime exposure to 
endogenous and exogenous sex hormone levels, are well-established risk factors for breast cancer 
(1-3).  Such associations are in line with findings from prospective studies which have consistently 
shown that higher circulating levels of estrogens and/or androgens in both pre- (4, 5) and post-
menopausal women (6) are associated with increased breast cancer risk.  Associations of risk with 
other hormones have been less consistent.  Previous studies have reported positive associations 
between prolactin levels and breast cancer risk, particularly amongst postmenopausal women (7) and 
post-menopausal HT users (8). Circulating levels of growth factors, such as insulin-like growth factor-I 
(IGF-I), have been associated with increased breast cancer risk in both pre- and post-menopausal 
women (9, 10). 
Mammographic density, a measure of the relative amounts of radio-dense fibro-glandular 
tissue to fat tissue in the breast as seen on a mammogram (i.e. the relative amounts of white radio- 
dense areas to black non-radio-dense areas), for a woman’s age and body mass index (BMI) is one 
of the strongest predictors of breast cancer risk (11). Mammographic percent-density increases with 
combined estrogen-progesterone HT use (12, 13) and decreases with tamoxifen use (14) and the 
menopause (15). However, current evidence on the relationship between breast-tissue composition 
and circulating levels of endogenous sex hormones and growth factors is mixed. BMI strongly 
influences the relationship between endogenous sex hormones and mammographic density as obese 
women have, on average, higher estradiol  levels and lower sex hormone-binding globulin (SHBG) (6) 
as well as lower percent mammographic density (15). Studies that have accounted for BMI have 
found sex hormone levels to be positively associated with mammographic density in premenopausal 
women (16-18).  Higher circulating levels of IGF-I, insulin growth factor binding protein-3 (IGFBP-3), 
IGF-I/IGFBP-3 molar ratio and growth hormone (GH) have been associated with increased 
mammographic density in pre-menopausal women in some (19), but not all (20), studies.  
To our knowledge no study has yet investigated the role of circulating sex hormones and 
growth factors on breast-tissue composition in women whose breast-tissue has not been influenced 
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by reproductive-related events, partly because mammography involves exposure to ionising radiation 
and hence cannot be performed in healthy young women.  Herein, we investigate the relationship 
between sex and growth hormone measures collected in adolescence and early adulthood and 
breast-tissue composition measured by radiation-free magnetic resonance imaging (MRI)(16, 21, 22), 
in young nulliparous women within a British pre-birth cohort. 
Method 
Study population 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective pre-birth cohort of 
14,775 children born in Avon, England, between April 1st 1991 and December 31st 1992 (23, 24).  The 
cohort represents 72% of the eligible population (23).  For the present primarily cross-sectional study, 
nulliparous women born from singleton pregnancies who participated in at least one follow-up survey 
were invited to attend an MRI examination of their breasts at the University of Bristol Clinical 
Research and Imaging Centre between June 2011 and November 2014.  Women who had MRI 
contra-indications (e.g. pregnancy, metal implants), or who had been diagnosed with cancer or a 
hormone-related disease, were excluded.  In all, 500 of 2,530 (20%) eligible women invited to 
participate attended an MRI examination (Figure 1).  The highly demanding nature of the study (e.g. 
time and travel to the MRI examination centre) and relocation away from the study area (i.e. to attend 
university) contributed to the low response rate.  Nevertheless, participants and non-participants were 
similar in relation to body size and available hormone measurements. For example, mean BMI and 
median testosterone blood levels at ~15.5 years were 21.3kg/m2 (standard deviation (SD)=3.1kg/m2) 
and 0.82nmol/L (inter-quartile range (IQR)=0.42nmol/L), respectively, amongst women who 
underwent the MRI examination, and 21·8kg/m2 (SD=3.8kg/m2) and 0.80nmol/L (IQR=0.45nmol/L), 
respectively, amongst those who did not.   
The study received approval from the South West Frenchay NRES Committee (11/SW/0051), the 
ALSPAC Law and Ethics Committee, and the London School of Hygiene and Tropical Medicine ethics 
committee. Participants provided written informed consent. 
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Blood sample collection at age 21.5 years  
A blood sample was taken from the participants on the same day they had their MRI breast 
examination, aged, on average, 21.5 (mean=21.5 (SD=0.92); Table 1) years. The samples were 
processed within 24 hrs, and plasma aliquots stored at -80oC. The blood sample for 2% of participants 
was collected after the MRI examination at their general practitioner clinics and sent by post to the 
ALSPAC laboratory. Figure 1 provides details on the number of samples that contributed to each 
hormone measurement, and reasons for exclusion.  
Hormone measurements at age 15.5 years 
Previously-conducted serum measurements of total testosterone and SHBG levels at age 15.5 
(mean=15.4 (SD=0.25)) years were available for a subset of participants (Figure 1). Total 
testosterone was measured using Agilent triple quadrupole 6410 liquid chromatography/mass 
spectrometry equipment with an electrospray ionization source operating in positive ion mode (Agilent 
Technologies, Wilmington, DE, USA). SHBG was measured using a Cobas Auto Analyzer (Roche 
Diagnostic, West Sussex, UK), and SHBG reagent using the manufacturer’s calibrators and quality 
control material. 
Hormone measurements at age 21.5 years 
Measurements of plasma sex steroid hormones and SHBG at age 21.5 were restricted to women who 
had not used hormone contraception during the 3 months prior to blood sample collection (n=117, 
Figure 1), and were performed at the Royal Marsden Hospital (laboratory of Prof. M Dowsett). 
Radioimmunoassay was used to determine plasma concentrations of testosterone (Indirect RIA, 
IM1087, Beckman Coulter), SHBG (IRMA-RIA-4184, DRG International, Inc), 
dehydroepiandrosterone (DHEA, RIA DSL 8900, Beckman Coulter), androstenedione (DSL 3800, 
Beckman Coulter) and prolactin (MG12161, IBL International). Assay sensitivities were 0.10nmol/L, 
0.41nmol/L, 0.21nmol/L, 0.31nmol/L and 10mIU/L, respectively. Between and within assay variation 
were, respectively, 5.1% and 13% for testosterone at 1.1nmol/l, 3.6% and 1.0% for SHBG at 75nmol/l, 
2.4% and 0.9% for DHEA at 21nmol/l, 8.3% and 4.9% for androstenedione at 3.1nmol/l, and 5.7% 
and 2.5% for prolactin at 503mIU/L. Estrone and estradiol were measured by indirect 
radioimmunoassay methods (25, 26) and the sensitivity of the assays was 15pmol/L and 3.0pmol/L, 
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respectively; their between and within assay variation were 16.0% and 6.6%  at 118pmol/l estrone, 
and 12.0% and 5.9% at 266pmol/l estradiol. 
Plasma levels of IGF-I, insulin-like growth-factor-II (IGF-II), IGFBP-3 and GH were measured in 
samples from 406 participants (Figure 1) at the University of Bristol (laboratory of Prof. J Holly) by in-
house radioimmunoassay method (IGF-I, IGF-II, IGFBP-3), and an ELISA (GH, Quantikine kit DGH00, 
R&D Systems), respectively. Measurement errors for IGFs are known to be low/moderate, with within 
and between coefficients of variation of 3.4% and 13.7%, 2.8% and 7.4%, 3.9% and 11.7%, and 3.1% 
and 7.8% for IGF-I, IGF-II, IGFBP-3 and GH, respectively (27). Molar ratios of IGF-I and IGF-II to 
IGFBP-3 were calculated as (0.13*(IGF-I or IGF-II)/(0.025*IGFBP-3).  
If the sample volume was too small for all laboratory measurements priority was given to the IGFs, 
GH and prolactin assays. Laboratory staff were blind to the characteristics of the participants. 
Participants in the MRI study for whom adolescent sex hormone measurements were, and were not 
available, were similar with respect to anthropometric and breast-measures. For example, mean age 
at menarche, BMI and percent-water at age 21.5 years were 12.7 (SD=1.00) years, 24.1 (SD=4.3) 
kg/m2 and 42.0% (SD=10.6%), respectively amongst those with testosterone measurement at age 
15.5 (n=330; Table 1), compared to 12.8 (SD=1.1) years, 23.6 (SD=4.4) kg/m2, and 41.4% (SD=9.8%) 
amongst those without such measurements. Similarly, among women who contributed to the hormone 
analyses, those with any sex hormone measurements (n=117; Table 1) were comparable to those for 
whom these were not possible (mean BMI=23.3 (SD=3.8) kg/m2 and percent-water=42.8% 
(SD=10.4%) at age 21.5 compared to BMI=23.8 (SD=4.1) kg/m2) and percent-water of 42.2% 
(SD=9.8%), respectively).    
Breast-tissue composition assessment 
Women underwent an examination of both breasts using a 3T Siemens Skyra MRI system. For each 
participant, a set of T1-weighted VIBE 3-D images (≈176 images/woman), with a voxel size of 
0.76x0.76x0.90mm3, and T2-weighted trans-axial images (≈40 images/woman), with in-plane 
resolution 0.85x0.85mm2 and slice thickness of 4mm were obtained. Fully-automated algorithms were 
developed to estimate breast volume using T1-weighted and T2-weighted images, whilst fat/water 
segmentations were completed on T2-weighted images. Left-right average estimates of volumes 
(cm3) of breast, water and fat (the latter two correspond to mammographic dense and non-dense 
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tissues, respectively), as well as percent-water, were generated.  In the same women, percent-water 
and mammographic percent-density are highly correlated (range r=0.76 to 0.85) (16, 21, 22).  Of the 
500 participants who had an MRI examination, valid breast parameters were produced for 491. A full 
description of the methodology, and of its validity, is given in Doran et al. (28).  
Covariates 
Information on anthropometric measures were collected from annual clinical assessments participants 
attended between ages 7 to 13 years and at ages 15 and 17 years. Annual questionnaires sent to 
participants between the ages 8 to 17 years collected pubertal and menstruation data. At the time of 
the MRI examination and blood sample collection for this study, participants completed a short 
questionnaire on menstrual-related variables, and anthropometric measurements were taken using a 
standard protocol. The study website contains details of all the data that are available through a fully 
searchable data dictionary (29). 
Statistical analysis 
MRI percent-water was the primary outcome of interest in the analysis given its well-established 
associations with breast cancer risk but, whenever appropriate, hormone associations with water and 
fat volumes were also investigated. Continuous hormone measurements were standardised (z-
scores), and MRI breast-tissue measures were log-transformed to achieve near-normal distributions. 
The relationship between participants’ hormone measurements and breast-tissue measures were 
examined using linear regression models. Exponentiated regression coefficients are shown; these 
coefficients represent the relative difference (RD) in breast-tissue measures associated with a unit 
increase in the exposure of interest (i.e. one SD for hormone levels). Non-linear relationships between 
hormone levels and breast-tissue measures were investigated and, if appropriate, are reported. Two 
types of models were fitted to the data. The first adjusted for assay batch number and storage time 
(number of months between blood sample being taken and analysed), and age, phase of menstrual 
cycle and hormone contraceptive-use at MRI examination and blood sample collection (Table 1). 
Phase of menstrual cycle (follicular, luteal. irregular) was estimated for women not using hormone 
contraception by calculating the number of days since last menstrual period (date of MRI – start of 
last menstrual period), and luteal (day 14-17 to 28-31) and follicular (day 0 to 14-17) phase, or an 
‘irregular period’ (32+ days) was defined using average length of menstrual cycle.  BMI at age 15.5 
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years, when the adolescent blood sample was taken, age of menarche, and history of contact with a 
doctor regarding their periods, were also investigated as possible confounding factors but inclusion of 
these additional variables in the models had little effect on the magnitude of the estimates – hence, 
these models are not presented. The second type of models were further adjusted for BMI at age 21.5 
years as it is unclear whether this variable should be treated as a confounder or a mediator for the 
hormone – breast-tissue associations. We also examined whether BMI at 21.5 years modified the 
hormone – breast-tissue associations.  
Data analyses were conducted in STATA, version 14 (StataCorp LP, College Station, TX). All tests of 
significance are two-sided. 
Results 
Study subjects 
Table 1 presents the characteristics of the participants and their distributions of hormone 
measurements and MRI breast-tissue composition estimates.   
Age of menarche was weakly correlated with circulating estradiol (r=0.19, p=0.044), whilst BMI at age 
21.5 years was inversely correlated with SHBG at ages 15.5 (r=-0.16, p=0.005) and 21.5 years (r=-
0.29, p=0.001), and with IGF-II at 21.5 years (r=-0.10, p=0.040) (Table S1). BMI at age 21.5 years 
was associated with MRI breast-measures, with a unit increase in BMI being associated with a 4% 
(RD=-0.04; 95% CI: -0.05, -0.04) lower percent-water but a 14% (0.14; 0.13, 0.15) and a 7% (0.07; 
0.06, 0.08) higher fat and water volumes, respectively (unadjusted estimates).  
Plasma sex hormones and MRI breast-measures 
Estradiol levels at age 21.5 were positively associated with percent-water, reflecting a more marked 
inverse association of this hormone with fat than water volume (Figure 1-model 1). These 
associations strengthened upon further adjustment for BMI at 21.5 years (Figure1-model 2), such that 
a one SD (=283.6pmol/L) increase in circulating estradiol was associated with a 3% (RD=1.03; 95% 
CI 1.00, 1.07) higher percent-water reflecting a 12% (0.88; 0.81, 0.98) lower fat volume and a 7% 
(0.93; 0.86, 1.01) lower water volume. Overall, there was no association between estrone levels and 
MRI breast-measures; however, analyses stratified according to BMI at MRI showed evidence that 
this variable modified the estrone – percent-water association, with estrone being positively 
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associated with percent-water (1.11; 1.03, 1.20) in overweight/obese (BMI≥25 kg/m2) participants but 
not in underweight/normal weight women (p for interaction=0.018; Table S2).     
SHBG levels at ages 15.5 and 21.5 were only weakly correlated (r=0.36, p<0.001). Nevertheless, 
SHBG levels at both these ages were positively associated with percent-water, driven mainly by 
inverse associations with fat volume (Figure 2-model 1). A one SD increase in SHBG levels at ages 
15.5 (SD=32.0nmol/L) and at 21.5 (SD=32.9nmol/L) was accompanied, respectively, by a 6% (1.06; 
1.03, 1.09) and a 7% (1.07; 1.02, 1.12) higher percent-water. These SHBG – percent-water 
associations were, however, attenuated upon further adjustment for BMI at MRI, particularly so for 
adult SHBG (Figure 2-model 2). 
There was no clear evidence of an association between DHEA and percent-water before (0.96; 0.92, 
1.01; Figure 1-model 1) or after further adjustment for BMI at MRI. There was, however, an inverse 
association between DHEA and water volume which was strengthened upon further adjustment for 
BMI at MRI (0.91; 0.84, 0.99). There was also evidence of a non-linear association between 
androstenedione and percent-water; relative to women in the lowest quartile those in the second 
lowest had a 4% (0.96; 0.87, 1.06) lower percent-water whilst those in the second and first highest 
quartiles had, respectively, a 2% (1.02; 0.92, 1.13) and 1% (1.01; 0.92, 1.12) higher percent-water 
(Table S3). Plasma testosterone levels at age 15.5 were weakly correlated with levels at age 21.5 
(r=0.45; p<0.001) despite the different measurement methodologies used (30).  Neither adolescent 
nor young adult testosterone levels were found to be associated with MRI breast-measures.   
Circulating levels of prolactin were not associated with MRI breast-measures overall, but there was 
evidence that BMI at MRI modified the association between prolactin and fat volume, with high levels 
of this hormone being associated with lower fat volume in overweight/obese participants only ((p for 
interaction=0.04; Table S2).  
There was no evidence that phase of menstrual cycle modified the sex hormone–percent-water 
associations but the power of the study to detect interactions was low. 
Plasma growth factors and MRI breast-measures 
Plasma levels of IGF-I and IGF-II were weakly correlated with each other (r=0.37, p=<0.001) and with 
IGFBP-3 (r=0.27, p=<0.001 and 0.39, p=<0.001, respectively). GH was not correlated with IGF-I 
(r=0.01, p=0.56), IGF-II (r=-0.01, p=0.91) or IGFBP-3(r=0.04, p=0.38).  The relationship between 
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circulating levels of growth factors and MRI breast-measures are presented in Figure 3. IGF-I and its 
IGF-I/IGFBP-3 molar ratio (molar ratio I) were both positively associated with percent-water, with 
these associations persisting upon further adjustment for BMI at MRI (1.02; 1.00, 1.04 and 1.02; 1.00, 
1.04, respectively).  The positive relationship between IGF-I and percent-water was driven by a more 
markedly lower fat volume (0.94; 0.90, 0.99) than water volume (0.97; 0.92, 1.02). Neither IGF-II, nor 
its IGF-II/IGFBP-3 molar ratio (molar ratio II), were found to be associated with MRI breast-measures 
(Figure 3). GH levels were also associated, albeit in a non-linear fashion, with percent-water (Figure 
4). In BMI-adjusted models, the top two GH quartiles were positively associated with percent-water, 
compared to the lowest GH quartile, and appeared to have a plateau effect (Table S3). Collapsing 
quartiles into a binary category, GH levels ≥1.65 ng/ml were associated with a 4% (1.04; 1.01, 1.08) 
higher percent-water relative to levels <1.65 ng/ml.  
There was weak evidence that IGFBP-3 was inversely associated with percent-water, with the 
magnitude of this association being little affected by further adjustment for BMI at MRI. This 
association was driven by a non-linear inverse association between IGFBP-3 and water volume, with 
young women in the second and third highest quartiles of the IGFBP-3 distribution having, 
respectively, a 5% (0.95; 0.90, 1.00) and a 4% (0.94; 0.90, 0.99) lower water volume compared to 
those in the lowest quartile in BMI-adjusted models (Table S3).          
Variability in MRI percent-water 
Sex hormones explained little of the variability in percent-water being lowest for testosterone at age 
15.5 (r2 adjusted for age, assay batch, storage time and the other hormone levels: 0.06%) and highest 
for SHBG at age 21.5 (adjusted-r2=7.7%). Growth hormone levels accounted for even less (adjusted-
r2<1.6% for all).  In contrast, BMI at MRI explained 54.4% of the variability in percent-water.  
Discussion 
Main findings 
In this unique study with endogenous sex and growth hormones measurements taken in adolescence 
and young adulthood, we found evidence of positive associations between estradiol at age 21.5 
years, and SHBG at ages 15.5 and 21.5 years, with MRI percent-water at age 21.5 years.  The 
magnitude of the young adult SHBG – percent-water association was slightly attenuated upon 
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adjustment for BMI at MRI; in contrast, the magnitude of the adolescent SHBG and young adult 
estradiol associations with percent-water were little affected upon such adjustment. Testosterone 
levels at ages 15.5 or 21.5 were not associated with any MRI breast-measures, but androstenedione 
level at 21.5 years was associated, albeit in a non-linear fashion, with percent-water. Young adult 
circulating levels of IGF-I and of GH were also associated with increases in percent-water, with these 
associations persisting after adjustment for concurrent BMI.  
Strengths and weaknesses 
To our knowledge, this is the first study to examine breast-tissue composition in young women prior to 
it being affected by reproductive-related events (e.g. pregnancies, breastfeeding). Other strengths of 
the study include the use of objective, and previously-validated, methods of assessing volumetric 
breast-tissue composition (28). The unique pre-birth cohort design meant that prospective 
standardised data on a wide range of childhood and adolescence variables, including certain 
adolescent hormone measurements, could be used alongside hormone measurements performed 
when participants were aged 21.5. But the study had some weaknesses. First, the participation rate 
was low (≈20%), albeit comparable to that of a similar MRI breast-tissue composition study of young 
women by Boyd et al. (16), reflecting the demanding nature of the study for participants (time and 
travel to the MRI examination centre). Second, blood samples could not be collected, or the amount 
collected was insufficient, for 16% of the participants. In addition, a high proportion of the participants 
had been on hormonal contraception in the 3 months prior to blood collection and hence were 
excluded from the sex hormone analyses. However, there was no evidence that participants for whom 
hormone measurements were available were a biased sample as they did not differ from the rest of 
the active ALSPAC cohort with regard to anthropometric or adolescent hormone measures, although 
by age 15.5 years the cohort was affected by socially-driven attrition (31). Furthermore, although 
response biases might have affected the sample’s representativeness it is unlikely that it would have 
distorted the associations between hormone levels and MRI breast-measures. Third, hormone and 
MRI breast measurements were taken at a single point in time and may not characterise long-term 
average levels. Plasma sex hormone levels change throughout the menstrual cycle, some markedly 
and some modestly. Small variations in breast density throughout the menstrual cycle have also been 
reported (32). It was logistically impossible to time the blood collection and the MRI examination to the 
menstrual cycle, but the participants’ menstrual phase was accounted for in the analysis. A previous 
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investigation (33) has shown that a single blood sample is sufficient to reliably characterise average 
levels of androgens, estrone sulfate, prolactin, and IGFs in pre-menopausal women over a 2-3 year 
period; however, reproducibility of a single measurement of estradiol and estrone was somewhat 
lower. GH secretion by the pituitary gland occurs in pulses throughout the day but again it was 
logistically impossible to time the blood collection to a particular time of the day (e.g. fasting morning 
samples). However, any errors in the measurement of plasma hormone/growth factors levels is likely 
to be non-differential as they were performed independently of the MRI ascertainment and hence the 
observed magnitude of the hormone – breast-measure associations is likely to be an under-estimation 
of the true magnitude of these associations. Fourth, hormone levels in young adulthood were 
measured at the time of the MRI breast examination making it impossible to establish temporality. The 
only exceptions were for testosterone and SHBG as plasma levels of these hormones at ages 15.5 
years were also available, with adolescent and young adult levels yielding associations with percent-
water of similar direction and magnitude. Finally, the high number of statistical tests performed may 
have led to spurious associations.  
Interpretation of the findings 
The study reveals positive associations between MRI percent-water in young women and concurrent 
circulating levels of IGF-I, and its molar ratio, consistent with mammography- and MRI-based findings 
reported by others (18, 19, 34), albeit not all (16, 20, 35), studies in pre-menopausal women. These 
associations are also in line with the reported positive association between IGF-I and breast cancer 
risk, albeit possibly restricted to oestrogen-receptor-positive tumours (9, 10), suggesting that the role 
of these hormones in the aetiology of this cancer may be mediated through their effect on breast-
tissue composition at young ages. This study also revealed a positive non-linear association between 
GH and percent-water. GH is the main mediator of postnatal somatic growth, exerting its effect 
directly by binding to receptors located on the membrane of target cells as well as indirectly by 
stimulating the production of IGF factors by the liver and other target organs, including the breast. A 
positive GH – percent-water association was reported by another study on the determinants of MRI 
breast-tissue composition in young women (16) although, in contrast to our study, it found no 
evidence of an association with IGF-I. Our findings are also consistent with previously reported 
positive associations of childhood growth and adult height with breast cancer risk (36) and breast 
density, as ascertained by percent mammographic density (37, 38) or MRI percent-water (16), 
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including with our previous findings from the ALSPAC cohort showing strong associations between 
childhood growth and MRI percent-water (39) .  
Our finding of a positive estradiol – percent-water association is consistent with results from two other 
studies which examined sex hormone levels throughout the menstrual cycle in relation to percent 
mammographic density (17, 34). However, the only other study to our knowledge to have examined 
the role of circulating sex hormones on MRI breast-tissue composition in young women found that 
percent-water was not associated with follicular levels of this hormone, but was inversely associated 
with luteal levels of free estradiol and free testosterone (16). Studies of the associations between sex 
hormone levels and mammographic density in postmenopausal women have produced mixed results 
(40, 41). 
The present study identified positive associations between SHBG at ages 15.5 and 21.5, and MRI 
percent-water at age 21.5, consistent with Boyd et al. (16). The direction of the observed association 
is, however, the opposite of the reported SHBG – breast cancer risk association (4, 5). The biological 
basis for the opposing effects on breast-tissue composition and cancer risk is unclear. Plasma SHBG 
not only binds to circulating steroids, thus regulating their bioavailability and access to target cells, but 
it also mediates the uptake of steroid molecules into cells through binding to cell-membrane 
receptors. The latter might stimulate intracellular messengers to cell proliferation and thus contribute 
to mitogenesis in the breast.  
Conclusion 
The study findings suggest that endogenous sex hormones and growth factors affect breast-tissue 
composition in young women. In particular, the associations of MRI percent breast water with GH and 
IGF-I, which are key mediators of postnatal somatic growth, suggests a potential biological 
mechanism for the well-established associations of childhood growth and adult height with breast-
tissue composition and, ultimately, breast cancer risk.  
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Table 1: Baseline characteristics of the participants, MRI breast-tissue composition measures, and 
plasma levels of sex hormones and growth factors 
 
  N 
Mean/
% 
SD Median IQR 
Participants characteristics at MRI examination 
Age (months) a 439 257.6 11.1 258.0 33.0 
BMI (kg/m2) 435 23.9 4.3 23.0 5.1 
Menstrual phase b Follicular 66 15    
 Luteal 44 10    
 Hormone contraceptives c 299 69    
 Irregular period 26 6    
MRI breast-measures d      
Left-right average breast volume (cm3)  438 649.8 465.3 507.8 471.8 
Left-right average breast fat volume (cm3) 438 408.9 353.8 293.9 332.3 
Left-right average breast water volume (cm3) 438 240.8 131.3 209.2 173.4 
Left-right average breast percent-water (%)  439 41.8 10.4 41.7 16.3 
Sex hormones      
At age 15.5 years      
Testosterone (nmol/L) 330 0.91 0.53 0.82 0.42 
SHBG (nmol/L) 318 64.1 32.0 58.1 37.5 
At age 21.5 years e      
DHEA (nmol/L) 115 28.6 12.8 26.0 16.0 
Androstenedione (nmol/L) 116 7.1 3.1 6.7 2.9 
Testosterone (nmol/L) 117 1.6 0.7 1.5 0.9 
Estrone (pmol/L) 109 260.7 159.9 223.0 150.0 
Estradiol (pmol/L) 115 318.6 283.6 196.0 255.0 
SHBG (nmol/L) 117 67.5 32.9 62.0 38.0 
Prolactin (mIU/L) f 399 264.1 135.4 234.0 135.0 
Growth factors at age 21.5 years 
IGF-I (ng/ml) 400 244.8 84.2 234.9 121.4 
IGF-II (ng/ml) 400 668.6 184.9 650.0 255.0 
IGFBP-3(ng/ml) 400 5509.9 1442.3 5607.1 1934.4 
IGF-I/IGFBP-3molar ratio g 400 0.25 0.13 0.23 0.12 
IGF-II/IGFBP-3molar ratio h 400 0.67 0.28 0.62 0.26 
GH (ng/ml) 400 3.8 4.8 1.7 5.7 
IQR: inter-quartile range; SD: standard deviation; BMI: body mass index; MRI: magnetic resonance imaging; 
SHBG: sex-hormone binding globulin; DHEA: dehydroepiandrosterone; IGF: insulin-like growth factor; IGFBP-3: 
insulin-like growth factor-binding protein 3; GH; growth hormone 
a After exclusion of 6 women with invalid MRI breast-measures, 439 participants had at least one hormone 
measurement in adolescence and/or at age 21 years 
b Estimated for women not using hormone contraception by calculating the number of days since last menstrual 
period (date of MRI – start of last menstrual period).  Luteal (day 14-17 to 28-31) and follicular (day 0 to 14-17) 
phase, and an ‘irregular period’ (32+ days) was defined using average length of menstrual cycle. 
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c Women who used hormone contraception at any time during the three months prior to blood collection.   
d Sections of the breast missing in the MRI images for one participant, thus volumetric measures cannot be 
ascertained and percent-water only used. 
e Sex hormone analysis, excluding prolactin, were carried out in women who had not used hormone 
contraception at any time during the 3 months prior to blood collection.  
f An outlier of 1,212mIU/L removed 
g Molar ratio I calculated as (0.13*IGF-I)/(0.025*IGFBP-3).  An outlier of 1.79 removed 
h Molar ratio II calculated as (0.13*IGF-II)/(0.025*IGFBP-3).  An outlier of 3.81 removed 
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Figure Legends 
 
Figure 1. Flowchart detailing patient selection, blood sample collection and hormone measurements.  
Figure 1 contains a flowchart detailing the inclusion of ALSPAC participants and collection of data for 
the study. 
 
Figure 2: Associations between plasma levels of sex hormones at ages 15.5 and 21.5 years (z-
scores) and MRI breast-tissue composition measures at age 21.5 years 
CI: confidence intervals; DHEA: dehydroepiandrosterone; MRI: magnetic resonance imaging; RD: 
relative difference per one standard deviation (SD) increase in plasma hormone levels; SHBG: sex-
hormone binding globulin.  
* Non-linear relationship results presented in Table 2. 
Plasma levels of sex hormones were standardised and MRI breast-measures were log transformed. 
Exponentiated estimated regression parameters are presented, with 95% CIs calculated by 
exponentiating the original 95% CIs. Model 1 adjusted for assay batch number, storage time, and age 
and menstrual phase at MRI examination; Model 2 further adjusted for BMI at MRI examination. 
Numbers contributing to these analyses are reported in Table 2:  DHEA n=114; Androstenedione 
n=115; Testosterone 15.5 years n=321; Testosterone 21.5 years n=116; Estrone n=108; Estradiol 
n=114; SHBG 15.5 years n=311; SHBG 21.5 years n=116; Prolactin n=389.   
 
Figure 3: Associations between plasma levels of growth factors (z-scores) at age 21.5 years and 
concurrent MRI breast-tissue composition measures 
CI: confidence intervals; IGF-I: insulin-like growth factor-I; IGF-II: insulin-like growth factor-II; IGFBP-3: 
insulin-like growth factor-binding protein 3; GH; growth hormone; MRI: magnetic resonance imaging; 
RD: relative difference per one standard deviation (SD) increase in plasma growth factor levels 
* Non-linear relationship – results presented in Figure 3 and Table S3. 
Plasma levels of growth factors were standardised and MRI breast-tissue composition measures were 
log transformed. Exponentiated estimated regression parameters are presented, with 95% CI 
calculated by exponentiating the original 95% CIs. Model 1 adjusted for assay batch number, storage 
time, and age and menstrual phase at MRI examination, and IGFBP-3 for IGF-I and IGF-II models, 
IGF-I for IGFBP-3 model, and IGF-II and IGFBP-3 for molar ratio I and IGF-I and IGFBP-3 for molar 
ratio II models. Model 2 further adjusted for BMI at MRI examination. 
a Molar ratio calculated as (0.13*IGF-I)/(0.025*IGFBP-3).  An outlier of 1.79 removed. 
b Molar ratio II calculated as (0.13*IGF-II)/(0.025*IGFBP-3).  An outlier of 3.81 removed 
Numbers contributing to these analyses are reported in Table 2: IGF-I n=396; IGF-II n=396; IGFBP-3 
n=396; Molar Ratio I n=395; Molar Ratio II n=395; GH n=396. 
 
Figure 4: Non-linear associations between plasma levels of growth hormone (GH) at age 21.5 years 
(z-scores) and concurrent MRI percent-water 
MRI: magnetic resonance imaging 
Plasma levels of growth hormone (GH) were standardised and MRI breast-tissue composition 
measures were log transformed. The fitted model shows the predicted estimates taking into account 
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the log transformation of MRI percent-water, and adjusting for assay batch number, storage time, and 
age, menstrual phase and BMI at MRI examination. 
 
